Skip to content
Biodatica
Start free

Ascentage Pharma Group Inc.

Houston, Texas

OncologyPhase III
Compare Sign in to watch

What changed

Phase II trial registered: A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

3w agoTrial registeredJun 22, 2026Source filing (opens the source filing in a new tab)

Momentum

84no change

Momentum 84 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

223 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Jan 22, 2025

    Higher-risk Myelodysplastic Syndrome · RECRUITING · sponsor: Ascentage Pharma Group Inc. · Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

    ClinicalTrials.gov · NCT06641414 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Mar 1, 2024

    Myelodysplastic Syndromes · ACTIVE_NOT_RECRUITING · sponsor: M.D. Anderson Cancer Center · A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

    ClinicalTrials.gov · NCT06113302 (opens the source filing in a new tab)

  3. Trial

    PHASE1/PHASE2 registered

    Sep 4, 2020

    Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome · TERMINATED · sponsor: M.D. Anderson Cancer Center · Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

    ClinicalTrials.gov · NCT04550442 (opens the source filing in a new tab)

  4. Trial

    PHASE1/PHASE2 registered

    Oct 1, 2019

    Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome · TERMINATED · sponsor: M.D. Anderson Cancer Center · Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

    ClinicalTrials.gov · NCT04160052 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources